Our earlier work has shown that HER2 overexpression is correlated with more aggressive disease in CRC patients [16], indicating that stratification of patients according to HER2 status might be beneficial in the early detection and subsequent therapeutic management of patients with metastatic CRC. Here, ERBB2 is linked to colorectal carcinoma.